Uracil mustard

DB00791ApprovedSmall molecule

Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage.

Mechanism: After activation, it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
Curator reviewed
Primary indication: Used for its antineoplastic properties.Curator reviewed
Formula / weight: C₈H₁₁Cl₂N₃O₂ · 252.098 g/mol (avg)
Also known as: 5-aminouracil mustard · Aminouracil mustard · Uracil nitrogen mustard · Uramustine
Code names: CB-4835 · NSC-34462 · SK-19849 · U-8344

Resolves to

Compound

UNIIW7KQ46GJ8UCAS66-75-1ChEMBLCHEMBL1488ChEBI9884PubChem6194KEGGD06265

Clinical / RWD

RxNorm10996ATCL01AD08PharmGKBPA451830

Structure

InChIKeyIDPUKCWIGUEADI-UHFFFAOYSA-NSMILESClCCN(CCCl)C1=CNC(=O)NC1=O

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 13 drug categories

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Uracil mustard, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account